Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan announces launch of generic Namenda Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda Tablets. [More]
New report highlights key success in global response to preventing AIDS in women, children

New report highlights key success in global response to preventing AIDS in women, children

The Elizabeth Glaser Pediatric AIDS Foundation applauds today's announcement from the Joint United Nations Programme on HIV/AIDS that the goal of providing 15 million people with lifesaving antiretroviral therapy (ART) by 2015 has been met nine months ahead of schedule. [More]
Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan announces launch of Bexarotene 75mg Capsules in U.S.

Mylan N.V. today announced the U.S. launch of Bexarotene 75mg Capsules, which is the generic version of Valeant's Targretin Capsules. This product is indicated for the treatment of cutaneous manifestations of cutaneous t-cell lymphoma in patients who are refractory to at least one prior systemic therapy. [More]
TSRI study reveals alternative approach to current anti-HIV strategies

TSRI study reveals alternative approach to current anti-HIV strategies

HIV-infected patients remain on antiretroviral therapy for life because the virus survives over the long-term in infected dormant cells. Interruption of current types of antiretroviral therapy results in a rebound of the virus and clinical progression to AIDS. [More]
Southern Research receives $22 million to support HIV cure initiative

Southern Research receives $22 million to support HIV cure initiative

Southern Research has been awarded a seven-year contract of up to $22 million to support research that could contribute to the cure of HIV disease. Under this contract, Southern Research will develop and standardize assays that quantitate latent reservoirs of HIV. [More]
Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

Researchers complete participants’ enrollment in Phase III trial of vaginal ring for HIV prevention

In a first for HIV prevention, an international team of researchers have completed follow-up of participants enrolled in a pivotal Phase III trial that tested the safety and effectiveness of a vaginal ring for preventing HIV in women. [More]
Innovations in AIDS efforts should be leveraged to meet future global health challenges, says UNAIDS-Lancet Commission

Innovations in AIDS efforts should be leveraged to meet future global health challenges, says UNAIDS-Lancet Commission

Countries most affected by HIV must focus on stopping new HIV infections and expanding access to antiretroviral treatment or risk the epidemic rebounding, urges a major new report from the UNAIDS and Lancet Commission. [More]
Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Implementation of needle exchange programs can prevent HIV outbreaks in Indiana

Congress needs to immediately lift the ban on federal funding for needle exchange programs to counter the threat of HIV outbreaks among injection drug users like the one that has seen an alarming number of new cases erupt in a single rural Indiana county. [More]
Single difference in HIV's genetic code influences progression of disease

Single difference in HIV's genetic code influences progression of disease

In a finding that furthers the understanding of human immunodeficiency virus (HIV), researchers from Children's Hospital Los Angeles discovered two locations where a single difference in HIV's genetic code altered the way the virus infected the cell, thereby influencing the progression of the disease. [More]
Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix signs ex-U.S. development agreement with Mylan for bronchodilator therapy

Pulmatrix, a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S. development agreement with Mylan N.V., one of the world's leading global pharmaceutical companies. [More]
WHO and World Bank Group: 400 million people do not have access to essential health services

WHO and World Bank Group: 400 million people do not have access to essential health services

A World Health Organization and World Bank Group report launched today shows that 400 million people do not have access to essential health services and 6% of people in low- and middle-income countries are tipped into or pushed further into extreme poverty because of health spending. [More]
HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

HIV-infected transgender women in US have unmet basic needs, less likely to achieve viral suppression

A new CDC study that combines 3 years of data to produce nationally representative estimates characterizing HIV-infected adults receiving care in the U.S. shows that those who identify as transgender women are significantly less likely to adhere to anti-HIV medication regimens and to achieve viral suppression. [More]
Protective antibody response could be effective in preventing mother-to-child HIV transmission

Protective antibody response could be effective in preventing mother-to-child HIV transmission

How most babies are protected from acquiring HIV from their infected mothers has been a matter of scientific controversy. [More]

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's tentative approval last week of lopinavir/ritonavir (LPV/r) oral pellets developed by the Indian generic company Cipla. [More]
Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Better treatment, prevention strategies still needed for opportunistic infections related to AIDS

Although treatment advances have dramatically reduced deaths from opportunistic infections related to AIDS, a new study drawing on 30 years of data from more than 20,000 patients in San Francisco suggests there is still ample room to improve. About a third--35 percent--of AIDS patients diagnosed with their first opportunistic infection from 1997 to 2012 in that city died within five years, according to the study, published in the Journal of Infectious Diseases. [More]
Earlier antiretroviral treatment benefits HIV-infected individuals

Earlier antiretroviral treatment benefits HIV-infected individuals

A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count--a key measure of immune system health--is higher, instead of waiting until the CD4+ cell count drops to lower levels. Together with data from previous studies showing that antiretroviral treatment reduced the risk of HIV transmission to uninfected sexual partners, these findings support offering treatment to everyone with HIV. [More]
Specific bacterial community in female genital tract induces inflammation, increases HIV risk

Specific bacterial community in female genital tract induces inflammation, increases HIV risk

A team led by researchers from Massachusetts General Hospital and the Ragon Institute of MGH, MIT and Harvard has found that the most common bacterial community in the genital tract among healthy South Africa women not only is significantly different from that of women in developed countries but also leads to elevated levels of inflammatory proteins. [More]
Study shows significant benefits of microclinics in rural Kenyan HIV patients

Study shows significant benefits of microclinics in rural Kenyan HIV patients

A team led by researchers from UC San Francisco, Organic Health Response, and Microclinic International is reporting results of a study that showed significant benefits of microclinics -- an innovative intervention that mobilized rural Kenyan HIV patients' informal social networks to support their staying in care. [More]
ART eligibility shorter for male HIV patients in rural South Africa

ART eligibility shorter for male HIV patients in rural South Africa

Male HIV patients in rural South Africa reach the low immunity levels required to become eligible for antiretroviral treatment in less than half the time it takes for immunity levels to drop to similar levels in women, according to new research from the University of Southampton. [More]

UNC-Chapel Hill, GSK partner to find cure for HIV/AIDS

The University of North Carolina at Chapel Hill, a leading global public research university with significant expertise in HIV basic and clinical research, and GSK, a global, research-based pharmaceutical and healthcare company with a legacy of success in developing treatments for HIV, today announced the creation of the dedicated HIV Cure center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. [More]
Advertisement